Acino ? Delivering Health

More documents

Recommendations

Info

In-house technologies Transdermal systems Location Miesbach, Germany Fentanyl & buprenorphine on the market, new formulations with USPs in development Rivastigmine EU submitted 2011, US submission targeted 2012 Development and production of a contraceptive patch for Bayer <strong>Health</strong>care Pharmaceuticals Additional customer projects under negotiation 10
In-house technologies Bio-degradable drug implants Location Miesbach, Germany Goserelin approved in several B2C markets, launch in Europe targeted 2013 Leuprorelin launch targeted for 2013 Customer projects are being evaluated Oral dispersibles Location Liesberg , Switzerland (and Miesbach, Germany) Technology for tablets (ODTs), films (ODFs) and pellets in stickpacks Project candidates under evaluation 11
Page 1 and 2: Acino - Delivering Health Annual Re
Page 3 and 4: 2011 operating performance EUR mill
Page 5 and 6: Balance sheet EUR million 31.12.201
Page 7 and 8: R&D and development pipeline Zurich
Page 9: In-house technologies Complex, soli
Page 13 and 14: From 2013 onwards 2-3 projects per
Page 15 and 16: “Old” Acino: highly dependent o
Page 17 and 18: 3-pillar business model of Acino Ac
Page 19 and 20: The acquisition includes: The marke
Page 21 and 22: Acquired business perfectly fits Ac
Page 23 and 24: The “new” Acino: broad customer
Page 25 and 26: Geographic break-down of revenue Ma
Page 27 and 28: Our past and future strengths Expan
Page 29 and 30: Key Facts: Acino TODAY Fourth large
Page 31: Acino - Delivering Health Thank you

Acino ? Delivering Health

Create successful ePaper yourself

Delete template?

Save as template?